Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):424-9. doi: 10.1016/j.clml.2013.03.006. Epub 2013 Jun 13.
Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported.
We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated.
Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P < .001).
Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.
来那度胺联合地塞米松适用于多发性骨髓瘤的治疗，也可单药用于骨髓增生异常综合征。皮疹的发生率和风险报道不一。
我们对文献进行了系统回顾和荟萃分析，以确定皮疹的发生率和风险。从 PubMed 和美国临床肿瘤学会年会上的摘要中确定了相关研究。计算了发生率、相对风险和 95%置信区间。
有 10 项试验可供分析，所有级别和高级别皮疹的总发生率分别为 27.2%和 3.6%。来那度胺与所有级别皮疹的风险增加相关（P<0.001）。
需要进一步研究以预防和治疗这种毒性，最大程度减少对生活质量和剂量强度的影响。
